Can an arthritis drug also help fatty liver? new study investigates.
NCT ID NCT06586281
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at 20 adults with psoriatic arthritis and fatty liver disease to see if the drug guselkumab can improve liver fat, joint swelling, and skin plaques. Participants will have two visits over 24 weeks to track changes. The goal is to understand shared disease mechanisms, not to provide a cure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-ALCOHOLIC FATTY LIVER DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of California, San Diego
RECRUITINGSan Diego, California, 92037, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could immune cells in fat hold the key to Obesity-Related disease?
- Can a new injection calm psoriatic arthritis?
- A new MRI technique could see inside the Liver's metabolism without a biopsy
- Can Weight-Loss surgery beat drugs for advanced liver damage?
- Can fatty liver in children lead to serious liver disease? a Long-Term study aims to find out
- Can a once-daily pill tame psoriatic arthritis in everyday life?